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CASE REPORT
Blastomycosis-like Pyoderma with Good Response to 
Acitretin
Young Seok Lee, M.D., Se Won Jung, M.D., Hyun Soo Sim, M.D., Jong Keun Seo, M.D.
1, 
Sook Kyung Lee, M.D.
Department of Dermatology, Maryknoll Medical Center,
1 College of Medicine, Inje University, Busan, Korea
Blastomycosis-like pyoderma is a rare, vegetating skin lesion 
that is an unusual exaggerated tissue reaction possibly to 
prolonged primary or secondary bacterial infection. We 
report a case of blastomycosis-like pyoderma in a man with 
Down syndrome, diabetes mellitus and hypothyroidism 
who responsed poorly to conventional therapies, including 
antibiotics and correction of predisposing factors for a long 
time, but experienced dramatic improvement after 3 months 




Blastomycosis-like pyoderma is an unusual, exaggerated, 
tissue reaction and usually only occurs in patients who are 
locally or systemically immunocompromised
1. The lesion 
consists of large, indurated, verrucous plaques. Histo-
pathologically, the lesion is characterized by pseudoepi-
theliomatous hyperplasia and intraepidermal, subepi-
dermal neutrophilic microabscesses
1. Although bacteria 
are likely to play a major role, response to antibiotics 
varies greatly
2. We report a case of blastomycosis-like 
pyoderma responding poorly to classic treatment, but 
responsed dramatically to treatment with acitretin. It may 
be thought that acitretin provides healing through 
anti-proliferative and anti-inflammatory action. Acitretin 
should be considered a good adjuvant modality for the 
treatment of blastomycosis-like pyoderma.
CASE REPORT
A 33 year-old man presented to our clinic in December 
2008 with verrucous cutaneous plaques on both ankles. 
He had been treated many times with occlusive dressing 
using topical steroid, antihistamines, antibiotics and 
antifungal agents by several dermatologists for 2 years 
before admission. These therapies resulted in some 
improvement but eventually the lesion deteriorated and 
spreaded. The patient’s past medical history included 
diabetes mellitus and hypothyroidism since the age of 23 
and 28 years, respectively. He also suffered mental 
retardation due to Down syndrome since birth. There was 
no history of trauma, consumption of bromides, and 
tuberculosis. Dermatologic examination revealed pruritic, 
irregular, lichenified verrucous plaques on both ankles 
and the right foot dorsum (Fig. 1). The lesion had elevated 
borders, extremely thick scales and excoriated 
hemorrhagic ulcers focally. Histopathologic examination 
of the biopsy specimen taken from verucous plaque 
showed pseudoepitheliomatous hyperplasia, neutrophil 
exocytosis, and papillary dermal microabscesses (Fig. 2A, 
B). In addition, perivascular and interstitial inflammatory 
infiltrates composed of lymphocytes, histiocytes, neutro-
phils, plasma cells, and eosinophils were observed in the 
dermis (Fig. 2C). No fungal elements were detected with 
periodic acid-Schiff stain. Bacterial culture of the tissue 
specimen revealed Staphylococcus aureus. Fungal and 
mycobacterial cultures were negative, and repeated KOH YS Lee, et al
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Fig. 1. (A) Lichenified verrucous 
plaques with hemorrhagic ulcers on
both ankles and right foot dorsum. 
(B) Close up view.
Fig. 2. (A) Histologic examination shows hyperkeratosis, 
pseudoepitheliomatous hyperplasia and dense inflammatory 
infiltrates in upper dermis (H&E, ×40). (B) The magnified view 
shows papillary dermal microabscess and neutrophil exocytosis 
(H&E, ×200). (C) Periappendageal dense mixed inflammatory 
infiltration of plasma cells and a few eosinophils (H&E, ×200).Blastomycosis-like Pyoderma with Good Response to Acitretin
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Fig. 3. The verrucous skin lesion improved after 3 months to 
the treatment with acitretin.
examinations of the scales at 1-month interval showed no 
hyphae or spores. On the basis of these findings, blasto-
mycosis-like pyoderma was diagnosed after excluding 
other diseases, such as lichen simplex chronicus, deep 
fungal and mycobacterial infections, bromoderma and 
neutrophilic dermatoses.
The patient was treated with antihistamines and daily oral 
antibiotics. There was no clinical response after 8 weeks 
and antibiotics were stopped. He was then given a daily 
oral dose of acitretin 20 mg, mequitazine 10 mg, 
bepotastine 20 mg, and gamma linoleic acid 80 mg with 
topical application of urea cream. After 3 months of 
therapy, the lesion resolved and only a mild scar was 
visible (Fig. 3). The total duration of treatment was 8 
months, and there were no adverse events associated with 
the treatment regimen, or evidence of recurrence for 9 
months.
DISCUSSION
Blastomycosis-like pyoderma most likely represents 
vegetating hyperinflammatory tissue reaction in a 
cutaneous environment with reduced immunological 
capacity
2. This disease of unknown etiology is believed to 
be associated with an excessive inflammatory reaction in 
response to bacterial infections, tattoos, foreign body 
reaction, halogens and immunodeficiency
3-5, such as 
diabetes mellitus, malnutrition, alcoholism, malignancy, 
HIV infection, and ulcerative colitis
4-6. 
In the skin lesions of the patients with blastomycosis-like 
pyoderma,  Staphylococci,  Streptococci,  Pseudomonas, 
Escherica coli, anaerobes and Candida species can be 
cultured
7. Among them, S. aureus is the most common
8. 
Some authors believe that the microbiological agent is not 
primarily responsible for the condition and the infection 
develops secondary to immune dysfunction
8,9. The condi-
tion fails to respond to antibiotic treatment alone, which 
supports this theory
8,10.
The characteristic lesions are large, crusted, verrucous 
plaques with pustules and well-defined and raised 
borders
11. These lesions are usually localized in the face, 
scalp, axilla, trunk, and distal extremities.
The histopathologic hallmarks of blastomycosis-like pyo-
derma are pseudo-epitheliomatous hyperplasia, intra-
epidermal, subepidermal microabscesses and dense 
dermal inflammatory infiltration
11,12. There is usually no 
granuloma formation.
The diagnostic criteria for blastomycosis-like pyoderma 
have been proposed as follows
13: 1) large verrucous 
plaques with multiple pustules and elevated borders, 2) 
pseudoepitheliomatous hyperplasia with abscesses in 
tissue biopsy specimens, 3) growth of at least one 
pathogenic bacterium, 4) negative cultures for deep fungi 
and mycobacteria, 5) normal serum bromide levels. Our 
patient met all these criteria. Serum halogen levels were 
not performed because there was no suggestion of 
halogen exposure in the history.
The differential diagnoses of the disease include North 
American blastomycosis, chromoblastomycosis, pyoderma 
gangrenosum, pemphigus vegetans, tuberculosis ver-
rucosa cutis, halogenoderma, and squamous cell 
carcinoma
3,12,14.
Numerous treatment modalities have been used, including 
topical and/or systemic antibiotics, retinoids, dapsone, 
cyclosporine, systemic corticosteroids, intralesional ste-
roids, surgical excision, cryosurgery and carbon dioxide 
laser
15. There is no standard treatment modality. In Korean 
dermatological literatures, Choi et al.
16 reported that 
treatment of blastomycosis-like pyoderma includes early 
bacterial culture with proper antibiotics, dressing with 
copper sulfate or aluminium subacetate, triamcinolone 
intralesional injection, zinc oxide, and disodium chro-
moglycate. Our treatment options can be summarized as 
follows: correction of the underlying disease, apply 
appropriate supportive wound care, administer specific 
antimicrobial, antihistamines and systemic retinoid 
therapy. Antibiotics were ineffective despite bacteria were 
isolated from tissue cultures, similar to previous reports of 
variable or poor response to antibiotics
2,17. There are 
reports of acitretin being used for treatment of 
blastomycosis-like pyoderma
2,18. Acitretin showed 
remarkable therapeutic effect and our patient’s lesions 
resolved after 3 months of therapy. Acitretin is a second YS Lee, et al
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generation retinoid and has specific biological activities 
that resemble those of vitamin A, such as anti-proliferative 
and anti-inflammatory activities
2,19.
We reported the therapeutic efficacy of acitretin in 
blastomycosis-like pyoderma unresponsive to antibiotics 
and topical steroids. Moreover, on the basis of the 
favorable adverse-effect profile of low-dose acitretin 
treatment, we recommend acitretin as the drug of choice 
for the treatment of blastomycosis-like pyoderma.
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